JP2016526023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526023A5 JP2016526023A5 JP2016513077A JP2016513077A JP2016526023A5 JP 2016526023 A5 JP2016526023 A5 JP 2016526023A5 JP 2016513077 A JP2016513077 A JP 2016513077A JP 2016513077 A JP2016513077 A JP 2016513077A JP 2016526023 A5 JP2016526023 A5 JP 2016526023A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- hydrogen
- aryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 136
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 239000001257 hydrogen Substances 0.000 claims description 60
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 102000013968 STAT6 Transcription Factor Human genes 0.000 claims description 3
- 108010011005 STAT6 Transcription Factor Proteins 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000006303 iodophenyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000001728 carbonyl compounds Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 0 CC(CC(*(C)[Cs])/C=I/*)S(C)*(C)N Chemical compound CC(CC(*(C)[Cs])/C=I/*)S(C)*(C)N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- -1 inhaler Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 208000036273 reactive airway disease Diseases 0.000 description 1
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361821181P | 2013-05-08 | 2013-05-08 | |
| US61/821,181 | 2013-05-08 | ||
| PCT/US2014/037342 WO2014182928A2 (en) | 2013-05-08 | 2014-05-08 | Stat6 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526023A JP2016526023A (ja) | 2016-09-01 |
| JP2016526023A5 true JP2016526023A5 (enExample) | 2017-06-15 |
Family
ID=51867868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513077A Withdrawn JP2016526023A (ja) | 2013-05-08 | 2014-05-08 | Ｓｔａｔ６阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9765099B2 (enExample) |
| EP (1) | EP2994143A4 (enExample) |
| JP (1) | JP2016526023A (enExample) |
| AU (1) | AU2014262621B2 (enExample) |
| CA (1) | CA2911914A1 (enExample) |
| WO (1) | WO2014182928A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190086392A1 (en) | 2016-03-21 | 2019-03-21 | Inserm (Institut National De La Sante Et De La Recherch Medicale) | Methods for diagnosis and treatment of solar lentigo |
| HRP20220479T1 (hr) | 2016-06-01 | 2022-05-27 | Athira Pharma, Inc. | Spojevi |
| SG11202110829YA (en) | 2019-04-05 | 2021-10-28 | Kymera Therapeutics Inc | Stat degraders and uses thereof |
| KR102444211B1 (ko) * | 2020-11-03 | 2022-09-16 | 이화여자대학교 산학협력단 | 비감염성 염증질환의 치료용 물질 스크리닝 방법 |
| WO2024064080A1 (en) * | 2022-09-19 | 2024-03-28 | Kymera Therapeutics, Inc. | Stat6 degraders and uses thereof |
| TW202425965A (zh) | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| WO2025103477A1 (en) * | 2023-11-17 | 2025-05-22 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025147320A1 (en) * | 2024-01-03 | 2025-07-10 | Kymera Therapeutics, Inc. | Stat6 inhibitors and uses thereof |
| WO2025217647A1 (en) * | 2024-04-12 | 2025-10-16 | Kymera Therapeutics, Inc. | Stat6 degraders and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08208462A (ja) * | 1994-11-24 | 1996-08-13 | Takeda Chem Ind Ltd | カテプシンｌ阻害剤 |
| AU3935895A (en) | 1994-11-24 | 1996-06-17 | Takeda Chemical Industries Ltd. | Alpha-ketoamide derivatives as cathepsin l inhibitor |
| WO1997012903A1 (en) * | 1995-10-04 | 1997-04-10 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins |
| AU2807197A (en) * | 1996-05-16 | 1997-12-05 | Warner-Lambert Company | Compounds inhibiting the association of the pdgf receptor and phosphatidylinositol 3-kinase and their use |
| CA2309792A1 (en) * | 1997-11-12 | 1999-05-20 | William C. Shakespeare | Novel signal transduction inhibitors, compositions containing them |
| US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
| JP2003525862A (ja) * | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害 |
| GB9925677D0 (en) | 1999-10-29 | 1999-12-29 | Pharmacia & Upjohn Spa | Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules |
| WO2001068655A2 (en) * | 2000-03-10 | 2001-09-20 | Ariad Pharmaceuticals, Inc. | Caprolactam derivatives and uses thereof |
| AU2000249828A1 (en) | 2000-05-03 | 2001-11-12 | Taisho Pharmaceutical Co. Ltd. | Stat4 and stat6 binding dipeptide derivatives |
| FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
| ATE530530T1 (de) | 2002-06-28 | 2011-11-15 | Astellas Pharma Inc | Diaminopyrimidincarbonsäureamidderivat |
| GB0415789D0 (en) * | 2004-07-15 | 2004-08-18 | Astrazeneca Ab | Novel combination |
| US20070010428A1 (en) * | 2004-09-03 | 2007-01-11 | Mcmurray John S | Inhibitors of signal transduction and activator of transcription 3 |
| US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
| WO2008070833A2 (en) * | 2006-12-07 | 2008-06-12 | University Of South Florida | Use of sh2 stat3/stat1 peptidomimetices as anticancer drugs |
| WO2010077589A2 (en) * | 2008-12-08 | 2010-07-08 | The Regents Of The University Of Michigan Office Of Technology Transfer | Stat3 inhibitors and therapeutic methods using the same |
| WO2010118241A2 (en) * | 2009-04-08 | 2010-10-14 | Indiana University Research & Technology Corporation | Inhibitors of protein tyrosine phosphatases |
| WO2010118309A2 (en) * | 2009-04-10 | 2010-10-14 | Board Of Regents, The University Of Texas System | Inhibitors of stat3 and uses thereof |
| WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
-
2014
- 2014-05-08 AU AU2014262621A patent/AU2014262621B2/en not_active Ceased
- 2014-05-08 EP EP14794359.1A patent/EP2994143A4/en not_active Withdrawn
- 2014-05-08 CA CA2911914A patent/CA2911914A1/en not_active Abandoned
- 2014-05-08 US US14/889,802 patent/US9765099B2/en not_active Expired - Fee Related
- 2014-05-08 JP JP2016513077A patent/JP2016526023A/ja not_active Withdrawn
- 2014-05-08 WO PCT/US2014/037342 patent/WO2014182928A2/en not_active Ceased
-
2017
- 2017-08-16 US US15/678,127 patent/US10385080B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526023A5 (enExample) | ||
| JP2009532417A5 (enExample) | ||
| JP2017518959A5 (enExample) | ||
| EA016203B1 (ru) | Производные амина | |
| JP2015509534A5 (enExample) | ||
| JP2008515852A5 (enExample) | ||
| JP2018509438A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2024523623A (ja) | Ｎｌｒｐ３インフラマソーム阻害剤 | |
| JP2013530179A5 (enExample) | ||
| JP2016500111A5 (enExample) | ||
| JP2016527220A5 (enExample) | ||
| JP2008195730A5 (enExample) | ||
| JP2015520738A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2009526037A (ja) | トリアゾロピリジン化合物 | |
| JP2014534222A5 (enExample) | ||
| JP2010540593A5 (enExample) | ||
| JP2016532677A5 (enExample) | ||
| JP2005525323A5 (enExample) | ||
| EA200970158A1 (ru) | Производные хинуклидина в качестве антагонистов м3 | |
| JP2015051983A5 (enExample) | ||
| JP2016510785A5 (enExample) | ||
| JP2010527984A5 (enExample) | ||
| JP2009543795A5 (enExample) |